Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 51.81 USD 1.79%
Market Cap: 5.4B USD
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

Corcept Therapeutics Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Corcept Therapeutics Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Corcept Therapeutics Inc
NASDAQ:CORT
Pre-Tax Income
$166.3m
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Pre-Tax Income
$17.6B
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Pre-Tax Income
-$6.9B
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Pre-Tax Income
$3.9B
CAGR 3-Years
-43%
CAGR 5-Years
-3%
CAGR 10-Years
-12%
Merck & Co Inc
NYSE:MRK
Pre-Tax Income
$13.7B
CAGR 3-Years
23%
CAGR 5-Years
4%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Pre-Tax Income
$10.2B
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
12%
No Stocks Found

Corcept Therapeutics Inc
Glance View

Market Cap
5.4B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Corcept Therapeutics Inc. is a biopharmaceutical company that has carved out a distinctive niche in the world of medicine by focusing on the development of drugs that modulate the effects of the hormone cortisol. Founded in 1998, the company is headquartered in Menlo Park, California. The real turning point for Corcept came when it developed mifepristone, branded as Korlym, approved by the FDA in 2012 for the treatment of Cushing's syndrome—a rare endocrine disorder characterized by excessive cortisol levels. Korlym works by mitigating the effects of excessive cortisol, providing relief from a range of debilitating symptoms. This first-in-class medication provided Corcept with a foothold in the industry, enabling it to build a sustainable revenue stream from a patient population with significant unmet medical needs. The business model of Corcept is primarily anchored in its innovative endocrinology portfolio, with a keen focus on expanding its therapeutic applications to other cortisol-related conditions. Beyond Korlym, the company’s pipeline includes an array of selective cortisol modulators aimed at exploring potential treatments for conditions such as antipsychotic-induced weight gain and various forms of cancer. This strategic orientation towards research and development is crucial for Corcept's growth, allowing it to leverage its expertise and proprietary technology to propel further success. Revenues are chiefly generated through the direct sale of Korlym in the United States, with ambitions to broaden its market reach as it seeks regulatory approvals for new indications and territories. This approach not only reinforces its commitment to considerable unmet needs in medicine but also positions Corcept as an influential force in the realm of cortisol modulation therapies.

CORT Intrinsic Value
70.39 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Corcept Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
166.3m USD

Based on the financial report for Sep 30, 2024, Corcept Therapeutics Inc's Pre-Tax Income amounts to 166.3m USD.

What is Corcept Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
9%

Over the last year, the Pre-Tax Income growth was 49%. The average annual Pre-Tax Income growth rates for Corcept Therapeutics Inc have been 12% over the past three years , 9% over the past five years .

Back to Top